Provided by Tiger Trade Technology Pte. Ltd.

Madrigal Pharmaceuticals

577.30
-8.9100-1.52%
Volume:220.90K
Turnover:127.55M
Market Cap:13.11B
PE:-44.29
High:593.00
Open:585.39
Low:573.00
Close:586.21
52wk High:605.00
52wk Low:265.00
Shares:22.71M
Float Shares:11.00M
Volume Ratio:0.93
T/O Rate:2.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-13.0355
EPS(LYR):-21.9007
ROE:-41.22%
ROA:-15.78%
PB:20.95
PE(LYR):-26.36

Loading ...

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Dec 05

Galmed Pharmaceuticals Granted New Patent for Combination of Aramchol and Rezdiffra (Resmetirom) for MASH Treatment

Reuters
·
Dec 04

Madrigal Pharmaceuticals CFO Mardi Dier Reports Disposal of Common Shares

Reuters
·
Dec 04

Madrigal Pharmaceuticals CCO Makes a Significant Stock Sale!

TIPRANKS
·
Nov 22

Madrigal Pharmaceuticals Chief Commercial Officer Carole Huntsman Reports Disposal of Common Shares

Reuters
·
Nov 22

Madrigal Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Nov 22

Strong Adoption and Market Expansion Drive Buy Rating for Madrigal Pharmaceuticals’ Rezdiffra

TIPRANKS
·
Nov 22

Madrigal price target raised to $620 from $568 at H.C. Wainwright

TIPRANKS
·
Nov 22

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Nov 21

Oppenheimer Adjusts Price Target on Madrigal Pharmaceuticals to $650 From $600, Maintains Outperform Rating

MT Newswires Live
·
Nov 20

U.S. RESEARCH ROUNDUP-Agios Pharmaceuticals, Dycom, Lowe's

Reuters
·
Nov 20

Madrigal Pharmaceuticals Inc : Oppenheimer Raises Target Price to $650 From $600

THOMSON REUTERS
·
Nov 20

Madrigal Pharmaceuticals Is Maintained at Buy by Truist Securities

Dow Jones
·
Nov 20

Madrigal Pharmaceuticals price target raised to $640 from $580 at Truist

TIPRANKS
·
Nov 19

Madrigal Pharmaceuticals (MDGL) Has a New Rating from Truist Financial

TIPRANKS
·
Nov 19

Assessing Madrigal Pharmaceuticals After FDA Approval and an 82% Share Price Surge

Simply Wall St.
·
Nov 18

Madrigal Pharmaceuticals to Join Jefferies Global Healthcare Conference

Reuters
·
Nov 17

Madrigal Pharmaceuticals Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Nov 14

Optimistic Buy Rating for Madrigal Pharmaceuticals Driven by Strong Drug Performance and Strategic European Expansion

TIPRANKS
·
Nov 13

Madrigal Pharmaceuticals price target raised to $587 from $526 at Canaccord

TIPRANKS
·
Nov 13